Literature DB >> 23879272

Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis.

Michele Boldrini1, Francesco Salinaro, Roberta Mussinelli, Ambra Raimondi, Alessio Alogna, Francesco Musca, Giovanni Palladini, Giampaolo Merlini, Stefano Perlini.   

Abstract

BACKGROUND AND
PURPOSE: To evaluate the prevalence and the prognostic implications of conduction delays in a large cohort of cardiac AL patients.
METHODS: Echo Doppler and 12-lead ECG were collected in 344 consecutive patients in whom diagnosis of AL amyloidosis was concluded between 2008 and 2010. Patients were subdivided according to the presence (n = 240) or absence (n = 104) of cardiac involvement.
RESULTS: When compared with patients without myocardial involvement, cardiac AL was associated with prolonged PQ, QRS, QT and QTc intervals (P < 0.05), and with higher prevalence of intraventricular blocks (27.5% vs. 16.5%, P < 0.05), that was associated with higher wall thickness, worse diastolic and regional systolic function, higher NT-proBNP values (all P < 0.05), and higher mortality (P = 0.0001; median follow-up: 402 days).
CONCLUSION: Intraventricular conduction delays have a negative prognostic impact in patients with cardiac AL amyloidosis. Their presence should not be overlooked in the diagnostic workup, prompting a more accurate cardiological support. ©2013, Wiley Periodicals, Inc.

Entities:  

Keywords:  amyloid; conduction disturbances; echocardiography; electrocardiography; prognosis

Mesh:

Substances:

Year:  2013        PMID: 23879272      PMCID: PMC6932035          DOI: 10.1111/anec.12032

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


  43 in total

1.  Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry.

Authors:  S Perlini; M L Muiesan; C Cuspidi; L Sampieri; B Trimarco; G P Aurigemma; E Agabiti-Rosei; G Mancia
Journal:  Circulation       Date:  2001-02-06       Impact factor: 29.690

2.  Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement.

Authors:  Blaithnead Murtagh; Stephen C Hammill; Morie A Gertz; Robert A Kyle; A Jamil Tajik; Martha Grogan
Journal:  Am J Cardiol       Date:  2005-02-15       Impact factor: 2.778

3.  A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.

Authors:  Giovanni Palladini; Paola Russo; Paolo Milani; Andrea Foli; Francesca Lavatelli; Mario Nuvolone; Stefano Perlini; Giampaolo Merlini
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

4.  Prognostic value of fragmented QRS in cardiac AL amyloidosis.

Authors:  Stefano Perlini; Francesco Salinaro; Francesco Cappelli; Federico Perfetto; Franco Bergesio; Alessio Alogna; Roberta Mussinelli; Michele Boldrini; Ambra Raimondi; Francesco Musca; Giovanni Palladini; Giampaolo Merlini
Journal:  Int J Cardiol       Date:  2012-06-27       Impact factor: 4.164

5.  Clinically significant cardiac amyloidosis. Clinicopathologic findings in 15 patients.

Authors:  L M Buja; N B Khoi; W C Roberts
Journal:  Am J Cardiol       Date:  1970-10       Impact factor: 2.778

6.  Right ventricular function in AL amyloidosis: characteristics and prognostic implication.

Authors:  Francesco Cappelli; Maria Cristina Porciani; Franco Bergesio; Stefano Perlini; Paola Attanà; Alberto Moggi Pignone; Francesco Salinaro; Francesco Musca; Luigi Padeletti; Federico Perfetto
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2011-12-16       Impact factor: 6.875

7.  Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis.

Authors:  J P Hamer; S Janssen; M H van Rijswijk; K I Lie
Journal:  Eur Heart J       Date:  1992-05       Impact factor: 29.983

8.  Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis.

Authors:  Belinda Ng; Lawreen H Connors; Ravin Davidoff; Martha Skinner; Rodney H Falk
Journal:  Arch Intern Med       Date:  2005-06-27

9.  Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death.

Authors:  Arnt V Kristen; Thomas J Dengler; Ute Hegenbart; Stefan O Schonland; Hartmut Goldschmidt; Falk-Udo Sack; Frederik Voss; Rüdiger Becker; Hugo A Katus; Alexander Bauer
Journal:  Heart Rhythm       Date:  2007-10-09       Impact factor: 6.343

10.  Gender-related risk of myocardial involvement in systemic amyloidosis.

Authors:  Claudio Rapezzi; Letizia Riva; Cristina C Quarta; Enrica Perugini; Fabrizio Salvi; Simone Longhi; Paolo Ciliberti; Francesca Pastorelli; Elena Biagini; Ornella Leone; Robin M T Cooke; Letizia Bacchi-Reggiani; Alessandra Ferlini; Michele Cavo; Giampaolo Merlini; Stefano Perlini; Sonia Pasquali; Angelo Branzi
Journal:  Amyloid       Date:  2008-03       Impact factor: 7.141

View more
  8 in total

Review 1.  New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.

Authors:  Stefano Perlini; Roberta Mussinelli; Francesco Salinaro
Journal:  Curr Heart Fail Rep       Date:  2016-12

2.  Direct Current Cardioversion of Atrial Arrhythmias in Adults With Cardiac Amyloidosis.

Authors:  Edward A El-Am; Angela Dispenzieri; Rowlens M Melduni; Naser M Ammash; Roger D White; David O Hodge; Peter A Noseworthy; Grace Lin; Sorin V Pislaru; Alexander C Egbe; Martha Grogan; Vuyisile T Nkomo
Journal:  J Am Coll Cardiol       Date:  2019-02-12       Impact factor: 24.094

Review 3.  Recent advances in the noninvasive strategies of cardiac amyloidosis.

Authors:  Lei Zhao; Quan Fang
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

Review 4.  Clinical management of amyloid cardiomyopathy.

Authors:  Morris M Kim; Clinton M Kolseth; Dayna Carlson; Ahmad Masri
Journal:  Heart Fail Rev       Date:  2021-09-01       Impact factor: 4.654

Review 5.  New Advanced Imaging Parameters and Biomarkers-A Step Forward in the Diagnosis and Prognosis of TTR Cardiomyopathy.

Authors:  Roxana Cristina Rimbas; Anca Balinisteanu; Stefania Lucia Magda; Simona Ionela Visoiu; Andrea Olivia Ciobanu; Elena Beganu; Alina Ioana Nicula; Dragos Vinereanu
Journal:  J Clin Med       Date:  2022-04-22       Impact factor: 4.964

Review 6.  Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques.

Authors:  Wael A Aljaroudi; Milind Y Desai; W H Wilson Tang; Dermot Phelan; Manuel D Cerqueira; Wael A Jaber
Journal:  J Nucl Cardiol       Date:  2014-04       Impact factor: 5.952

7.  Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement.

Authors:  Diana Bonderman; Gerhard Pölzl; Klemens Ablasser; Hermine Agis; Stefan Aschauer; Michaela Auer-Grumbach; Christina Binder; Jakob Dörler; Franz Duca; Christian Ebner; Marcus Hacker; Renate Kain; Andreas Kammerlander; Matthias Koschutnik; Alexander Stephan Kroiss; Agnes Mayr; Christian Nitsche; Peter P Rainer; Susanne Reiter-Malmqvist; Matthias Schneider; Roland Schwarz; Nicolas Verheyen; Thomas Weber; Marc Michael Zaruba; Roza Badr Eslam; Martin Hülsmann; Julia Mascherbauer
Journal:  Wien Klin Wochenschr       Date:  2020-12-03       Impact factor: 1.704

8.  Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities.

Authors:  Michele Orini; Adam J Graham; Ana Martinez-Naharro; Christopher M Andrews; Antonio de Marvao; Ben Statton; Stuart A Cook; Declan P O'Regan; Philip N Hawkins; Yoram Rudy; Marianna Fontana; Pier D Lambiase
Journal:  J Am Heart Assoc       Date:  2019-09-08       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.